FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163017622> ?p ?o ?g. }

• W2163017622 endingPage "1382" @default.
• W2163017622 startingPage "1378" @default.
• W2163017622 abstract "<h3>Objectives</h3> Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterised by synovitis and joint destruction. The pathogenesis of RA is not clear, but is considered to be an immune-mediated inflammatory disorder, in which the complement system plays an important role. Although cell-derived microparticles (MPs) have been associated with inflammation and complement activation, it is unknown whether MPs are either cause or consequence. Therefore, we investigated whether circulating MPs differ between patients with very early as yet untreated arthritis and healthy controls, and whether intensive anti-inflammatory treatment of such patients affects circulating MPs. <h3>Methods</h3> Patients with RA (n=24) and controls (n=15) were included. Nine patients with RA were re-evaluated after 8 weeks of intensive treatment with a combination of drugs (‘COmBination therapy in Rheumatoid Arthritis’ (COBRA) scheme). Disease activity was measured by erythrocyte sedimentation rate (ESR), C reactive protein (CRP) and Disease Activity Score for 28 joints (DAS28). Flow cytometry was used to study MPs and exposure of complement activator molecules and complement components. <h3>Results</h3> At baseline, concentrations of MPs exposing C1q, CRP or serum amyloid-P (SAP)were all significantly elevated in patients with early RA compared to controls (p=0.003, p=0.002 and p=0.003, respectively). Upon treatment, DAS28 score, ESR and CRP levels significantly decreased (p=0.008, p=0.008 and p=0.012), but the concentrations of circulating MPs and MPs exposing complement components or activator molecules were unaffected. <h3>Conclusion</h3> Circulating MPs exposing complement components or activator molecules are elevated in early RA. Since a strong anti-inflammatory therapy suppressed inflammation in patients with early RA but not levels of circulating MPs, it is unlikely that inflammation is the main underlying cause of MP release in these patients." @default.
• W2163017622 created "2016-06-24" @default.
• W2163017622 creator A5003239706 @default.
• W2163017622 creator A5027096828 @default.
• W2163017622 creator A5028880756 @default.
• W2163017622 creator A5029733252 @default.
• W2163017622 creator A5044831604 @default.
• W2163017622 creator A5063016107 @default.
• W2163017622 creator A5067384016 @default.
• W2163017622 creator A5068474395 @default.
• W2163017622 creator A5081799498 @default.
• W2163017622 creator A5085213730 @default.
• W2163017622 date "2009-11-16" @default.
• W2163017622 modified "2023-10-11" @default.
• W2163017622 title "Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis" @default.
• W2163017622 cites W1493824599 @default.
• W2163017622 cites W1965434732 @default.
• W2163017622 cites W1984883105 @default.
• W2163017622 cites W1990787424 @default.
• W2163017622 cites W2000832741 @default.
• W2163017622 cites W2008794458 @default.
• W2163017622 cites W2011709265 @default.
• W2163017622 cites W2017269547 @default.
• W2163017622 cites W2030383998 @default.
• W2163017622 cites W2030977071 @default.
• W2163017622 cites W2036816398 @default.
• W2163017622 cites W2059009304 @default.
• W2163017622 cites W2074438676 @default.
• W2163017622 cites W2076607145 @default.
• W2163017622 cites W2099920676 @default.
• W2163017622 cites W2115068422 @default.
• W2163017622 cites W2126017233 @default.
• W2163017622 cites W2142232425 @default.
• W2163017622 cites W2144058261 @default.
• W2163017622 cites W2151098475 @default.
• W2163017622 cites W2152348310 @default.
• W2163017622 cites W2156051763 @default.
• W2163017622 cites W2157590557 @default.
• W2163017622 cites W2165683921 @default.
• W2163017622 cites W76725777 @default.
• W2163017622 doi "https://doi.org/10.1136/ard.2009.118372" @default.
• W2163017622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19919943" @default.
• W2163017622 hasPublicationYear "2009" @default.
• W2163017622 type Work @default.
• W2163017622 sameAs 2163017622 @default.
• W2163017622 citedByCount "37" @default.
• W2163017622 countsByYear W21630176222012 @default.
• W2163017622 countsByYear W21630176222013 @default.
• W2163017622 countsByYear W21630176222014 @default.
• W2163017622 countsByYear W21630176222015 @default.
• W2163017622 countsByYear W21630176222016 @default.
• W2163017622 countsByYear W21630176222017 @default.
• W2163017622 countsByYear W21630176222018 @default.
• W2163017622 countsByYear W21630176222019 @default.
• W2163017622 countsByYear W21630176222020 @default.
• W2163017622 countsByYear W21630176222021 @default.
• W2163017622 countsByYear W21630176222022 @default.
• W2163017622 countsByYear W21630176222023 @default.
• W2163017622 crossrefType "journal-article" @default.
• W2163017622 hasAuthorship W2163017622A5003239706 @default.
• W2163017622 hasAuthorship W2163017622A5027096828 @default.
• W2163017622 hasAuthorship W2163017622A5028880756 @default.
• W2163017622 hasAuthorship W2163017622A5029733252 @default.
• W2163017622 hasAuthorship W2163017622A5044831604 @default.
• W2163017622 hasAuthorship W2163017622A5063016107 @default.
• W2163017622 hasAuthorship W2163017622A5067384016 @default.
• W2163017622 hasAuthorship W2163017622A5068474395 @default.
• W2163017622 hasAuthorship W2163017622A5081799498 @default.
• W2163017622 hasAuthorship W2163017622A5085213730 @default.
• W2163017622 hasBestOaLocation W21630176222 @default.
• W2163017622 hasConcept C111684460 @default.
• W2163017622 hasConcept C126322002 @default.
• W2163017622 hasConcept C203014093 @default.
• W2163017622 hasConcept C2776821229 @default.
• W2163017622 hasConcept C2776914184 @default.
• W2163017622 hasConcept C2777077863 @default.
• W2163017622 hasConcept C2777575956 @default.
• W2163017622 hasConcept C2778143017 @default.
• W2163017622 hasConcept C2779244835 @default.
• W2163017622 hasConcept C2780942790 @default.
• W2163017622 hasConcept C71924100 @default.
• W2163017622 hasConcept C8891405 @default.
• W2163017622 hasConceptScore W2163017622C111684460 @default.
• W2163017622 hasConceptScore W2163017622C126322002 @default.
• W2163017622 hasConceptScore W2163017622C203014093 @default.
• W2163017622 hasConceptScore W2163017622C2776821229 @default.
• W2163017622 hasConceptScore W2163017622C2776914184 @default.
• W2163017622 hasConceptScore W2163017622C2777077863 @default.
• W2163017622 hasConceptScore W2163017622C2777575956 @default.
• W2163017622 hasConceptScore W2163017622C2778143017 @default.
• W2163017622 hasConceptScore W2163017622C2779244835 @default.
• W2163017622 hasConceptScore W2163017622C2780942790 @default.
• W2163017622 hasConceptScore W2163017622C71924100 @default.
• W2163017622 hasConceptScore W2163017622C8891405 @default.
• W2163017622 hasIssue "7" @default.
• W2163017622 hasLocation W21630176221 @default.
• W2163017622 hasLocation W21630176222 @default.
• W2163017622 hasLocation W21630176223 @default.

• next